Our experience of holmium laser enucleation of the prostate


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Surgical treatment of benign prostatic hyperplasia (BPH) is influenced by a rapidly growing number of technologies. Aim. To determine the surgical potential ofholmium laser enucleation of the prostate (HoLEP) and the rate of postoperative complications during the learning curve. Materials and methods. A total of 98 patients undergoing HoLEP in the surgical department of the Clinical Hospital “Mother & Child” during the period from January 2018 to May 2020 were included in the study. HoLEP was performed by a single surgeon with previous experience in transurethral procedures. The criteria for inclusion in the study group were as follows: moderate-to-severe lower urinary tract symptoms, prostate volume > 40 cm3, maximum flow <15 ml/ sec, the volume of residual urine > 50 ml. The exclusion criteria were the following: inflammatory process in the lower urinary tract, genitourinary malignancy, previous urinary tract interventions. The evaluated criteria included age, prostate size, International Prostate Symptoms Score (IPSS and QoL), bladder diary, PSA, uroflowmetry, total operative time, length of catheterization, complications according to the Clavien-Dindo Classification, and length of stay. Results. During pathologic study, two cases of incidental prostate cancer (2.1%) were detected. The relationships between the prostate size and operative time (p<0.05), operative time and length of stay (p<0.05) were found. The total rate of complications was 16.3%. There were no complications >IIIb according to the Clavien-Dindo Classification. The most dangerous complications were injuries of the bladder wall and ureteral orifice (31.25% and 18.75% among all complications, respectively). Discussion. It should be considered that a large "middle lobe" is associated with a high risk of injury of the ureteral orifices. In our series, there were 5 cases of bladder tamponade, while bladder injuries during the morcellation developed in the first 10 patients. Conclusion. HoLEP is a reasonable alternative to TURP for surgical treatment of BPH and is considered a safe procedure for patients taking anticoagulant and antiplatelet drugs. Past experience of TURP allows to learn the technique faster and to reduce the number of complications.

Full Text

Restricted Access

About the authors

M. M Kutluev

Clinical Hospital “Mother & Child” Uf

Email: marrat@rambler.ru
Ph.D, Urologist at the Surgical Department Ufa

R. I Safiullin

Clinical Hospital “Mother & Child” Uf; Bashkir State Medical University

Email: russafiullin@yandex.ru
Ph.D., MD, professor at the Department of Urology Ufa; Ufa

References

  1. Nguyen D.D., Misray V., Bach T., Bhojani N., Lingeman J.E., Elterman D.S., Zorn K.C. Operative time of aquablation, greenlight PVP, ThuLEP, GreenLEP, and HoLEP. World J. Urol. 2020;39(2). doi: 10.1007/s0345-020-03137-8.
  2. Moution M., Michel C., Bourgi A., Baumert H. Holmium laser Enucleation of the prostate: Analysis of early complications. Patient selection for day-case surgery. Prog. Urol. 2020;30(2):89-96.
  3. Kampantais S., Dimopoulos P., Tasleem A., Acher P., Gordon K., Young A. Assessing the learning curve of holmium laser Enucleation of prostate (HoLEP). A systematic review. Urology. 2018;120:9-22.
  4. Kim K.H., Kim K.T., Oh J.K., Chung K.J., Yoon S.J., Jung H., Kim T.B. Enucleated weight/Enucleation time, is it appropriate for estimating Enucleation skills for holmium laser Enucleation of the prostate? A consideration of energy consumption. World J. Mens Health. 2018;36(1):79-86.
  5. Пешехонов К.С., Шпиленя Е.С., Комяков Б.К., Бурлака О.О., Саргасян М.С. Сравнительный анализ резекционной и энуклеацинной методик эндоскопического лечения гиперплазии предстательной железы у пациентов пожилого возраста. Вестник урологии. 2020;8(1):25-38.
  6. Павлов В.Н., Капранов С.А., Сафиуллин Р.И., Плечев В.В., Галимов О.В., Ишметов В.Ш., Папоян А.О., Ибрагимов Т.Р., Благодаров С.И., Завьялов К.И. Первый опыт эмболизации простатических артерий в лечении больных доброкачественной гиперплазией простаты. Креативная хирургия и онкология. 2018;8(1):28-32.
  7. Глыбочко П.В., Аляев Ю.Г., Рапопорт Л.М., Еникеев Д.В., Охунов Ж., Нэтш К., Спивак Л.Г., Тараткин М.С. Эндоскопическая энуклеация простаты: временный тренд или новый стандарт лечения. Урология. 2018; 2:130-33.
  8. EAU Guidelines on Treatment of Non-neurogenic Male LUTS 2018.
  9. Sun F., Sun X., Shi Q., Zhai Y. Transurethral procedure in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications. Medicine (Baltimore). 2018;97(51):e13360. doi: 10.1097/MD.0000000000013360
  10. Красулин В.В., Глухов В.П., Васильев К.С. Современные возможности хирургического лечения гиперплазии предстательной железы. Вестник Урологии. 2019;7(2):85-92.
  11. Kim M., Lee H., Oh S. Technical aspects of Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia. Korean J. Urol. 2013. Sep 54(9):570-579.
  12. Хубларов О.Ю. Гольмиевая лазерная энуклеация простаты, особенности выполнения вмешательства. Вестник Урологии. 2014;2:25-40).
  13. Herrmann T. R. Enucleation is enucleation is enucleation is enucleation. World J. Urol 2016;34(10):1353-1355. doi: 10.1007/s00345-016-1922-3. PMID: 27585786.
  14. Bach T., Muschter R., Sroka R. et al. Laser treatment of benign prostatic obstruction: basics and physical differences. Eur. Urol 2012;61(2):317-25. doi: 10.1016/j.eururo.2011.10.009.PMID: 22033173.
  15. Kuntz, R.M., et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol, 2008.53:160.
  16. Naspro R., et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. Eur Urol. 2006.50:563.
  17. Sun, J. et al. Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) on patients receiving dual antiplatelet therapy (DAPT). World J Urol. 2018.36:271.
  18. Abedi A.R. Ghiasy S., Fallah-Karkan M., Rahavian A., Allameh F. Tha management of patient diagnosed with incidental prostate cancer: narrative review. Res. Rep. Urol. 2020;(12): 105-09. doi: 10.2147/RRU.S245669.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies